Veriheal

JULY 16, 2020

Despite the novelty of its drug policy findings, the document has gone largely unnoticed by reform advocates and the media. The panel, led by Jake Leinenkugel (a presidential nominee), asserted that psychedelics, such as MDMA and psilocybin, as well as cannabis, present promising ways to treat mental health conditions among military veterans.

Research and Development 97

Research and Development Clinical Trials Treatment Compliance 97

Cannabis Law Report

JUNE 24, 2022

The legislation from Senate President Nicholas Scutari (D), who has long championed cannabis reform in the Garden State, would further create a system of licensed businesses to provide psilocybin services in supervised settings. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow.

Access 52

Access Therapy Clinical Trials Treatment 52

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. The program imposes strict limitations on the THC content in the prescribed cannabis, ensuring that it remains at a very low level.

Law 52

Law Dispensary Clinical Trials Programs 52

MMJ Recs

DECEMBER 22, 2023

As the United States navigates through a complex web of legal, social, and medical considerations, public opinion on medical cannabis has evolved significantly over the years. The changing public opinion is evident in the increasing number of states legalizing medical cannabis and the growing support for such measures.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

SEPTEMBER 22, 2021

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Veriheal

MAY 12, 2021

The relationship between cannabis and cancer has long been at the forefront of research regarding its medical efficacy, mainly for legalization and treatment purposes. However, cannabis use amongst those with cancer is poorly understood, at least according to a team of researchers. years old.

Patients 98

Patients Consumption Clinical Trials Education 98

United Patients Group

JANUARY 8, 2023

Cannabis and the Immune System. Cannabis and the Immune System. In fact, cannabis has been used for thousands of years as a medicine. Cannabis has also been used for centuries to treat gastrointestinal disorders, epilepsy, rheumatism and malaria. Cannabis has Antiviral, Antibacterial and Fungal Properties.

Blood Pressure 105

Blood Pressure Sleep Cannabinoids Clinical Trials 105

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

APRIL 21, 2022

MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

NOVEMBER 29, 2019

Euractiv report… Germany’s regulatory approach to medical cannabis is good practice and should be replicated across Europe, according to newly-born European Medicinal Cannabis Association (EUMCA). Lack of clinical trials is a major reason why doctors are cautious about the drug. Read full story.

Medicine 59

Medicine Clinical Trials Treatment Access 59

SpeedWeed

MARCH 5, 2021

Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. Bilmoria opine: “[R]emoving cannabis from Schedule I of the CSA would mean that it could be treated as any other physician-prescribed drug. Authors Tracy Gallegos and Neville M.

Business 52

Business Policy Clinical Trials Research and Development 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Source: [link].

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 29, 2021

of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products. The levels of these compounds in dried mushrooms are only 0.2% – 1.0% ” About Nova Mentis Life Science Corp.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. One group self-administered cannabis with 12% THC over three weeks.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Veriheal

MARCH 23, 2023

One of the proposed bills would amend the Cannabis Control Law during the current 150-day Diet session, which launched on Monday, January 23. Based on Japan’s Cannabis Control Law—A.K.A. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products. ‘1948 Law No.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Cannabis Law Report

JANUARY 19, 2022

He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives. We look forward to his guidance in helping us bring new, THC-based investigational medications into FDA approved clinical trials. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

OCTOBER 17, 2019

(Tree of Knowledge) (CSE:TOKI) (OTC:TOKIF) expands global medical marijuana and CBD research in partnership with the Caribbean Institute of Pharmacy Policy (CIPPPAR) in Jamaica. Currently, the Company has research agreements with multiple universities for medical cannabis research and new medical grade products development.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JUNE 9, 2022

Ukraine’s Health Minister Viktor Liashko announced on June 7 that the government had backed the bill that would legalize medical cannabis amid the war with Russia. We understand the number of people who will need medical treatment due to this exposure. “We understand the negative effects of war on mental health.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. Learn more at www.immunoflex.com.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JULY 13, 2019

report…… Proposals to name and shame businesses that fail to provide cannabis drugs for use in U.K. clinical trials have been made by Members of Parliament. It concludes that the main reason so few NHS cannabis prescriptions have been made in the U.K. CBD Testers.co THE REPORT. Read Abstract & Link at.

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

Cannabis Law Report

MARCH 29, 2022

With Mike, MAPS PBC is taking another major step in building a world-class pharmaceutical organization capable of meeting the enormous need for novel treatments for PTSD and other mental health conditions. He brings to MAPS PBC a wealth of experience in drug development, expertise in drug commercialization, and a global perspective.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

JUNE 19, 2022

The new center is designed to formalize a network of experts across the university based in a range of academic departments as well as existing centers focused on drug policy and substance misuse prevention and recovery. Alan Davis. Our capacity to reach so many makes this commitment essential.”.

Education 52

Education Research and Development Therapy Clinical Trials 52

Cannabis Law Report

APRIL 10, 2019

Here’s a quick precis care of Cannabis Wire Daily Newswire. In November, UK law changed to allow clinicians to prescribe medical cannabis under limited conditions. Just over 80 prescriptions for medical cannabis (THC and CBD) have been written, according to Hancock. “We Can we unlock the door?”.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

JUNE 1, 2021

Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

The Cannigma

JUNE 15, 2021

Like all plants, cannabis contains a plethora of molecules, some of which have specific functions — such as determining the smell, taste and color of the plant, but also what types of effects it can have on you. This is why eating raw cannabis won’t necessarily get you high — it is full of non-decarboxylated THCA. CBD vs THC.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JULY 15, 2019

PUBLISHER: CANNABIS LAW REPORT. July 18 marks the first anniversary of the Portuguese medical cannabis law. The major merit of Decree Law 8/2019 was to provide a clear distinction between cannabis-based medicinal products, cannabis-based preparations and cannabis-based substances (dried flower and oils).

Medicine 40

Medicine Clinical Trials Patients Access 40